Aims To investigate whether strong cardiac sympathetic activity contributes primarily to sudden death or to worsening heart failure, and to determine the relationship of the size of cardiac noradrenaline stores to the mode of death.
Introduction
Sympathetic nervous activity is increased in patients with congestive heart failure [1] , accompanied by depletion of myocardial noradrenaline stores [2] , and 1-adrenoreceptor downregulation [3] and desensitization [4] . Strong sympathetic tone is associated with poor outcome [5, 6] and its inhibition by -receptor antagonists positively affects prognosis in congestive heart failure [7, 8] . Data from our laboratory suggested that stimulation of the cardiac sympathetic nervous system, rather than generalized sympathetic activation, was primarily related to poor outcome [6] . However, it remains to be determined whether this relationship is primarily mediated through an ongoing adverse effect on ventricular function leading to death from progressive cardiac failure or by predisposition to ventricular arrhythmias and sudden death. Perhaps both mechanisms are operating. Additionally, whether measures of cardiac sympathetic nervous system other than its activity have any influence on mode of death in congestive heart failure is unknown.
Thus, we sought (1) to investigate whether high cardiac sympathetic activity, as assessed by the isotope dilution method, contributes primarily to sudden death, to worsening of congestive heart failure, or to both, (2) to determine the relationship, if any, of the cardiac noradrenaline synthesis rate, which is increased in congestive heart failure [9] , and the size of cardiac noradrenaline stores to the mode of death, and (3) to investigate whether these measures of the cardiac sympathetic nervous system are helpful in understanding the pathophysiology of sudden and non-sudden death in congestive heart failure.
Methods

Study population
The study population comprised 116 patients (98 male, 18 female, mean age 53 8 years) with moderate to severe congestive heart failure who were referred to our hospital for pre-transplant assessment. All patients were studied and followed prospectively over a period of up to 78 months. All patients had a left ventricular ejection fraction c45% secondary to coronary artery disease in 54 (47%), dilated cardiomyopathy in 59 (51%), and valvular heart disease in three (3%) patients (Table 1) . At baseline patients underwent clinical assessment, right heart catheterization, assessment of sympathetic nervous function with noradrenaline isotope dilution methodology, and radionuclide measurement of left ventricular ejection fraction. At the time of study, 97% were on ACE-inhibitors, 97% on diuretics, 81% on digoxin, 24% on amiodarone, and 7% on beta-blockers ( Table 1 ). The protocol was approved by the Alfred Hospital Ethics Review Committee, and patients gave informed consent to participate in the study.
Procedures Catheterization
Patients were studied in the morning after refraining from smoking and consumption of caffeinated beverages overnight. A 3F-cannula was inserted into a radial or brachial artery for monitoring of blood pressure and blood sampling. Pulmonary artery pressure measurements (mean and wedge) were recorded, using a SwanGanz catheter. Cardiac output was measured by thermodilution. After the haemodynamic evaluation, a catheter (Webster CCS 7/8U 90A), advanced under fluoroscopic control into the coronary sinus, was used to sample coronary sinus blood and measure coronary sinus blood flow by thermodilution.
Estimation of whole body and cardiac sympathetic activity
Measurements of the spillover of noradrenaline to plasma from the heart and the body as a whole were used to estimate cardiac and overall sympathetic activity [10] . All patients received an intravenous infusion of tritiated levo-noradrenaline (New England Nuclear) at a rate 0·5-1·5 Ci . min 1 . Arterial and coronary sinus blood samples were drawn simultaneously at least 30 min after radiotracer infusion was begun. Plasma was separated by centrifugation at 4 C and stored at 80 C until analysis. The total (SP NE tot) and cardiac (SP NECard ) noradrenaline spillover rate to the plasma were measured using methods developed by us [11] : 
SP NECard =[(NE CS -NE A )+(NE A ER)] Q P
where NE CS and NE A are coronary sinus and arterial plasma noradrenaline concentration, respectively; ER the fractional extraction of tracer noradrenaline across the heart and Q P coronary sinus plasma flow. 
Estimation of cardiac noradrenaline synthesis rate
Cardiac overflow of dihydroxyphenylalanine (DOPA), which is not extracted materially by the heart and is proportional to rates of noradrenaline synthesis [2, 12] , was estimated from the arterial-venous difference in plasma concentration and coronary plasma flow. are coronary sinus and arterial plasma concentration of endogenous DHPG, respectively. Patients were divided into those with large (specific activity of DHPG produced by the heart above median) and those with small (specific activity of DHPG produced by the heart below median) noradrenaline vesicular stores.
Quantification of cardiac noradrenaline stores
Assays
Catecholamines in plasma (1 ml) and samples of the infusion preparation (10 l) were adsorbed on to alumina and quantified by liquid chromatography with electrochemical detection as previously described [13] . Timed collections of the eluant as it leaves the electrochemical cell enable separation of [ 3 H]-DHPG and noradrenaline for assay by liquid scintillation spectrometry.
Follow-up
Follow-up was achieved by interview of referring physicians, patients and/or relatives and through patient visits in the Alfred Hospital. Sudden death was defined as death occurring within 1 h of symptom onset or during sleep without prior progression of congestive heart failure. Non-sudden death was defined as death in the setting of progressive deterioration of cardiac function. One patient had a non-cardiac death and in another patient, a left ventricular assist device was implanted. Both patients and those undergoing transplantation were censored from further analysis at the time of event.
Statistical analysis
Values are expressed as mean SD and as frequencies as indicated. Survival was calculated using the KaplanMeier method. The significance of each variable as a prognostic marker was first tested univariately using log-rank test for categorical and Cox proportional hazards model for continuous variables. Variables identified as significantly associated with outcome were examined multivariately using the stepwise Cox proportional hazards model. The significance of each variable was tested for overall cardiac mortality as well as for non-sudden and sudden death separately. A P-value of c0·05 was considered to show a statistically significant difference.
Results
Patients' characteristics are shown in Table 1 . Thirty-six (31%) patients died after a median follow-up of 10·3 months (mean 17·7 18·7). Of those, 20 died suddenly and 16 from progression of congestive heart failure. Forty (34%) patients underwent heart transplantation 10·9 11·5 months (range 0·5-61·0) after enrolment in the study. Actuarial survival after 1, 2 and 3 years was 79% (n=54), 68% (n=29), and 55% (n=19), respectively.
Predictors of cardiac mortality
Univariate survival analysis revealed that cardiac noradrenaline spillover and DOPA overflow were strongly related to cardiac mortality. Arterial noradrenaline concentration, resultant from whole body spillover and clearance, was also a good predictor of prognosis. In addition, elevated mean pulmonary artery and wedge pressure and low serum sodium were related to cardiac mortality (Table 2) . In multivariate analysis, cardiac noradrenaline spillover (hazard ratio= 3·43 per nmol . min 1 , 95% confidence interval 1·13-10·4, P<0·05), cardiac DOPA overflow (hazard ratio= 5·3 per nmol . min 1 , 95% confidence interval 1·65-15·4, P<0·01) and cardiac extraction of radiolabelled noradrenaline (hazard ratio=0·97 per %, 95% confidence interval 0·95-0·99, P<0·005) were the only independent predictors of cardiac mortality. Baseline medication did not show any relation to cardiac mortality.
Predictors of death from worsening heart failure
Cardiac noradrenaline spillover and DOPA overflow were strong predictors of non-sudden death (Table 2 ). In addition, cardiac extraction of radiolabelled noradrenaline and cardiac noradrenaline stores (inversely correlated to specific activity of DHPG produced by the heart) were also related to non-sudden death. Additionally, serum sodium, pulmonary artery and wedge pressures, and mean arterial pressure were related to non-sudden death. In multivariate analysis, cardiac noradrenaline spillover (hazard ratio=7·00 per nmol . 1 . min 1 , 95% confidence interval 1·29-38·0, P<0·05), specific activity of DHPG produced by the heart (hazard ratio=1·04 per dpm . pmol 1 , 95% confidence interval 1·01-1·08, P<0·05, i.e. small noradrenaline stores), cardiac DOPA overflow (hazard ratio=13·99 per nmol . 1 . min 1 95% confidence interval 2·63-74·2, P<0·01), and sodium concentration (hazard ratio=0·86 per mmol . l 1 , 95% confidence interval 0·77-0·97, P<0·05) were independent predictors of non-sudden death. Again, these results were not influenced by the baseline medication. Figure 1 depicts cumulative hazard curves of nonsudden death in patients divided in tertiles of cardiac noradrenaline spillover and patients with estimated large and small noradrenaline stores, respectively. The lowest tertile of cardiac noradrenaline spillover approximately equated to the range of values found in healthy subjects [2, 10] . Patients with high cardiac noradrenaline spillover despite small noradrenaline stores were at particular risk of non-sudden death (Fig. 2) .
Predictors of sudden death
In contrast to non-sudden death, sudden death was related to large cardiac noradrenaline stores (Fig. 1) . In addition, predictors of sudden death included left ventricular ejection fraction, ischaemic heart disease, arterial noradrenaline concentration, whole body noradrenaline spillover, and pulmonary wedge pressure, but not baseline medication (Table 2 ). In addition, cardiac noradrenaline spillover divided into tertiles was related to sudden death (hazard ratio=1·64 per group, 95% confidence interval 1·08-2·47, P=0·02, Fig. 1 ). Although cardiac noradrenaline stores were larger in patients with ischaemic as compared to non-ischaemic cardiomyopathy (specific activity of DHPG produced by the heart 7·4 6·7 vs 11·4 13·5 dpm . nmol 1 , P<0·05), ischaemic aetiology (hazard ratio=3·36, 95% confidence interval 1·21-9·33, P=0·02) and specific activity of DHPG produced by the heart (hazard ratio 0·94 per dpm . min 1 , 95% confidence interval 0·89-0·99, P=0·02, i.e. large noradrenaline stores) were related to sudden death independent of each other. In addition, cardiac noradrenaline spillover divided into tertiles (hazard ratio=1·94 per group, 95% confidence interval 1·07-3·53, P=0·03) and left ventricular ejection fraction (hazard ratio=0·92 per %, 95% confidence interval 0·85-1·00, P=0·05) were independent predictors of sudden death in multivariate analysis. Figure 2 reveals that patients with high cardiac noradrenaline spillover and large noradrenaline stores were at particular risk of sudden death.
Discussion
There is growing evidence that elevated cardiac sympathetic activity plays an important role in the pathophysiology of congestive heart failure. Our study expands on earlier findings in many ways. Firstly, high cardiac sympathetic activity and increased noradrenaline synthesis as assessed by DOPA overflow [12, 14] were strongly 
HR=hazard ratio; 95% CI=95% confidence interval; EF=ejection fraction; CAD=coronary artery disease; MAP=mean arterial pressure; MPAP=mean pulmonary artery pressure; MPWP=mean pulmonary wedge pressure; NA=noradrenaline; ER=fractional extraction of [ 3 H]noradrenaline; TNASR=whole body NA spillover rate; CNASR=cardiac NA spillover rate; CDOPA=cardiac DOPA overflow; SA DHPG =normalized specific activity of DHPG produced by the heart. Hazard ratio, given for predictor with Pc0·05, refers to units in parentheses.
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associated with death from worsening congestive heart failure, whereas sudden death was related to a variety of different parameters. Secondly, depletion of neuronal noradrenaline stores, as assessed by specific activity of DHPG produced within the sympathetic nerves of the heart [2] , and reduced uptake of radiolabelled noradrenaline by the cardiac sympathetic nerves were associated with death from worsening congestive heart failure. These latter findings support the idea that the integrity of sympathetic innervation becomes defective as congestive heart failure progresses. Thirdly, large neuronal noradrenaline stores independently contributed to the risk of sudden death. This might indicate that, in contrast to more advanced congestive heart failure, sympathetic innervation may still be sufficiently intact at less advanced stages to permit surges of sympathetic activation contributing to arrhythmogenesis and sudden death.
Measures of sympathetic activity and prognosis
Although advances in therapy have improved prognosis in congestive heart failure, morbidity and mortality remain high. In a large study investigating patients after myocardial infarction, autonomic imbalance as assessed by baroreflex sensitivity and heart rate variability was found to facilitate cardiac death, particularly if the left ventricular function was reduced [15] . In addition, it has long been recognized that plasma noradrenaline in the peripheral blood as a measure of overall sympathetic activation carries independent prognostic significance [16] . However, plasma noradrenaline cannot be taken to represent cardiac sympathetic activity because the heart contributes only a few percent to the total noradrenaline pool [11, 17] , and sympathetic activation exhibits organ specificity, with the heart being selectively affected first in milder grades of congestive heart failure [18] . Our study indicates that cardiac sympathetic activation is an important predictor of and probably contributor to adverse outcome in congestive heart failure.
Relationship of cardiac sympathetic activity and noradrenaline stores to worsening heart failure death
This study reveals a very strong influence of cardiac sympathetic activation on progression of congestive heart failure leading to death. Only hyponatraemia, a known indicator of poor outcome [19] , was an additional Figure 1 Cumulative incidence of death due to worsening heart failure (HFD; top) and sudden death (SD; bottom) in patients divided into tertiles of cardiac noradrenaline (NE) spillover (left) and small and large cardiac noradrenaline stores (right). Low cardiac noradrenaline spillover was associated with a low incidence of both non-sudden and sudden death. However, cardiac noradrenaline spillover, in the intermediate to high range, was not discriminatory for sudden death. Whereas small cardiac noradrenaline stores were related to a high incidence of non-sudden death, large stores were related to sudden death. independent predictor of non-sudden death. The strong influence of chronic cardiac sympathetic activation on progression of congestive heart failure is concordant with observations that long-term sympathetic activation contributes to progressive cardiac myocyte dysfunction, loss of cardiac myocytes, and ventricular remodelling [20] . Cardiac DOPA overflow was a strong predictor of cardiac mortality, particularly due to progression of disease, indicating increased noradrenaline synthesis was associated with progression of congestive heart failure, independently of cardiac noradrenaline spillover. Cardiac DOPA overflow is closely related to cardiac tyrosine hydroxylase activity, the rate-limiting step in catecholamine biosynthesis [21] . DOPA appearing in coronary sinus plasma is derived primarily from cardiac sympathetic nerves [22, 23] , and rates of DOPA overflow are thus proportional to rates of noradrenaline synthesis [2, 12] and are increased in patients with congestive heart failure [9] . Noradrenaline stores are reduced in patients with congestive heart failure [2] . Our data indicate that this is associated with progression of congestive heart failure. Several factors may be responsible for the depletion of noradrenaline stores. Neuronal noradrenaline reuptake seems to be impaired in the failing human heart although this does not directly imply abnormal function of the membrane transporter [2] . Preliminary data seem to indicate that uptake-1 transporter sites per neuron are not diminished in congestive heart failure, while sympathetic nerve terminals are reduced as compared to normal hearts, suggesting there is neuronal attrition in the failing human heart [24] . Our recent finding of a reduction in nerve growth factor in advanced congestive heart failure may possibly supply an explanation of this loss of sympathetic fibres from the heart [25] . Additionally, noradrenaline synthesis may be insufficient in congestive heart failure patients since the increase in noradrenaline synthesis in another situation accompanied by intense sympathetic stimulation (physical exercise) is proportionally much less than the increase in noradrenaline release [12] , due to a limited increase in tyrosine hydroxylase activity [26] . These findings may be interpreted to mean that, even though ongoing high cardiac sympathetic activation is a contributor to the progression of congestive heart failure, in some instances leading to non-sudden death, the sympathetic innervation progressively deteriorates during the course of congestive heart failure, reflected in reduced size of cardiac noradrenaline stores [2] . This might result in limiting cardiac functional reserve in some subjects who are dependent on adrenergic support. In addition, although not proven by our results, it is possible that a further reflex increase in noradrenaline release is limited, thereby preventing the heart from being exposed to excessively high surges of noradrenaline, and decreasing the risk of development of serious arrhythmias in end-stage congestive heart failure. This formulation is supported by our earlier finding that the increase in noradrenaline spillover with laboratory stressors is, in fact, less in congestive heart failure patients than in healthy volunteers [2] . As congestive heart failure progresses, worsening congestive heart failure becomes the main cause of death [27] and sudden death is often caused by bradyarrhythmias and electro-mechanical dissociation [28] .
Relationship of sympathetic activity to sudden death
Sudden death may be caused by a variety of different mechanisms [29, 30] . In our study, ischaemic heart disease, known to trigger arrhythmias particularly in the setting of elevated sympathetic activity [31] , was an independent predictor of sudden death. In addition, as previously reported [32] , decreased ejection fraction was associated with sudden death. Reduction of ejection fraction may be associated with the extent of remodelling of the left ventricle, thereby facilitating arrhythmias [29] . Sympathetic activation may provoke arrhythmias through its ability to alter the structure (remodelling, 
Cardiac sympathetic nervous activity in CHF 1141
fibrosis) and function of the failing heart. 1- [33] and 1-adrenoreceptor [34] stimulation can facilitate abnormal automaticity and triggered activity [35] . In addition, by acting on 2-receptors, catecholamines increase the transport of potassium into the cell, thereby increasing the risk of hypokalaemia [30] . Finally, thrombosis, by platelet activation [36] , and plaque rupture, the most common underlying mechanisms of sudden death [37] , have been associated with high sympathetic activity [38] . In animal models of coronary artery disease, ventricular fibrillation was associated with activation of the sympathetic nervous system [39] , and in patients with sustained ventricular arrhythmias, systolic dysfunction accompanied by increased cardiac sympathetic activity has been described [40] . Moreover, circadian variability of acute coronary events and sudden death has been related to a simultaneous increase in sympathetic nervous activity [41] , whereas circadian variability is lacking in patients on beta-blocking agents [42] . In our study, increased cardiac and whole body noradrenaline spillover were associated with risk of sudden death. More importantly, large cardiac noradrenaline stores were significantly and independently related to sudden death, indicating increased risk of sudden death in patients with intact cardiac sympathetic innervation. Thus, it may be speculated that acute sympathetic stimulation may result in surges of noradrenaline release in these patients, thereby increasing the risk of serious arrhythmias.
Limitations
Our study is unable to directly answer the question of whether acute elevations of sympathetic activity directly trigger serious arrhythmias in congestive heart failure patients, leading to sudden death. Our data support this assumption in those patients with normal cardiac noradrenaline stores, but not those with evidence of sympathetic denervation.
Ours was a cross-sectional study, and changes from baseline in cardiac sympathetic activity may have occurred progressively during the course of follow-up. Additionally, an influence of changes in therapy on our results cannot be excluded.
Finally, the interpretation of our results is limited by the relatively small number of deaths in our study population and the proportionately large number of subjects who underwent cardiac transplantation whose data were censored at that time. However, it is important to note that this is the largest series of patients who have undergone assessment of cardiac sympathetic nervous activity by the radiotracer dilution method so far.
Conclusions
Our study underlines the importance of cardiac sympathetic activation to prognosis in congestive heart failure. Moreover, our data provide evidence that the cardiac sympathetic nervous system is involved in both nonsudden and sudden death, but by different pathophysiological mechanisms. In advanced congestive heart failure, a high prevailing level of cardiac sympathetic activity is a major contributor to progression of congestive heart failure, but integrity of cardiac sympathetic innervation seems to be defective, thereby decreasing the risk of neuronal triggering of serious tachyarrhythmias and sudden death. In contrast, when cardiac noradrenaline stores and sympathetic innervation are intact in congestive heart failure patients, sudden death is more frequent, as triggering stimuli can be translated into surges of noradrenaline release within the heart, predisposing to tachyarrhythmias.
Thus, it may be hypothesized that antiadrenergic drugs will prove to be beneficial not only in symptomatic [7, 8] but also in early and/or asymptomatic heart failure where cardiac sympathetic innervation is still intact and tachyarrhythmia is the main cause of death. Further studies will be needed to indicate, which of the available antiadrenergic measures, selective or nonselective 1-blockade, combined -and 1-blockade, or central inhibition of sympathetic nervous outflow will most effectively prevent sudden death. In the future, there may possibly be a place in clinical management for measurement of cardiac catecholamine kinetics, which is comparable in technical complexity to electrophysiological studies, in detecting congestive heart failure patients at high risk for sudden death, who would profit most from internal cardioverter/defibrillator placement and in selecting patients suitable for cardiac transplantation.
